CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Increase of number of shares and votes in Hansa Medical AB (publ)

31 Jul 2018, 08:00
Regulatory information
As previously announced, the general meeting of Hansa Medical AB (publ) resolved to adopt a warrant program 2015-2019 on June 2, 2015. As part of the completion of the program, 50,000 ordinary shares have been issued. The company’s registered share capital and number of outstanding shares and votes have thus increased during the month of July 2018.

As of today, the total number of registered and outstanding shares of Hansa Medical amounts to 38,463,386 whereof 38,133,125 are ordinary shares and 330,261 are Class C shares. As of today, the number of votes in Hansa Medical amounts to 38,166,151.1 and the registered share capital amounts to SEK 38,463,386.

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 8:00 am CEST on July 31, 2018.

Files

For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: 46707175477
E-mail: emanuel.bjorne@hansamedical.com

About Hansa Medical
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, imlifidase (IdeS), is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin-cleaving enzymes are developed for repeat dosing with the objective of applying the Hansa Medical technology in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, and its shares are listed on Nasdaq Stockholm (ticker: HMED).